Weight loss,
your way

Personalized GLP-1 programs, tailored by your
medical team, at accessible prices.

Weight loss potential with Ivím^*

41.8lbs

lbs Your current weight

^*Average weight loss based on 68 and 72 week clinical trials studying semaglutide (2.4 mg) and tirzepatide (10-15 mg) in patients without diabetes and with BMI ≥30, or BMI ≥27 with a weight-related health condition, the average weight loss was 15% and 20% respectively. Neither of these studies evaluated compounded semaglutide or compounded tirzepatide.

Weight loss medications that actually work

Lose up to 20% body weight
after 1 year of use^†

Lose up to 20% body weight
after 1 year
of use^†

^† Ozempic®, WeGovy®, Saxenda®, and Victoza® are registered trademarks of Novo Nordisk. Zepbound™ and Mounjaro® are registered trademarks of Eli Lilly. Ivím is not affiliated with Novo Nordisk or Eli Lilly, and the compounded products offered by Ivím are not produced by these companies. Compounded medications may be prescribed based on personal weight loss needs. While federal law allows the prescription of compounded drugs, they are not FDA-approved and do not undergo safety, effectiveness, or manufacturing review.

The Ivím difference

Personalized expert care

Medical specialists tailoring your weight loss journey.

Exclusive mobile app access

Track your progress and instantly connect with your care team.

Strength in numbers

Gain insights and inspiration from peers in our community space.

Insurance is optional, quality care is not

Our insurance specialists excel where others fail, ensuring you have the best possible chance to get covered. Should your insurance deem you ineligible, we offer affordably priced programs so you can still achieve your weight loss goals.